Loading
companiesCompany
ALFA (Acute Leukemia French Association)
aka Acute Leukemia French Association, ALFA group, ALFA group (France)
ALFA is the French adult acute myeloid leukaemia cooperative group, an association founded in 1998 of clinicians, biologists and research assistants across 33 centres; in OnCo it leads ALFA-0701, the trial that brought gemtuzumab ozogamicin back.
Overview
The Acute Leukemia French Association (ALFA) is an association under the French law of 1901 founded in 1998, composed of clinicians, biologists and clinical research assistants and devoted to the treatment of acute myeloid leukaemia in adults and to research in that field, with 33 centres in France (alfa-leukemia.org). Its website lists member centres but no registered office, so no seat is given here. ClinicalTrials.gov names it lead sponsor (OTHER class, with Versailles Hospital as collaborator) of ALFA-0701 (NCT00927498, phase 3, fractionated gemtuzumab ozogamicin added to daunorubicin and cytarabine in newly diagnosed AML aged 50 to 70), the trial recorded in OnCo. It has no products of its own.
Headquarters
France (seat not stated), FR
Website
Founded
1998
Similar pages
not linked directly; found by shared links- CompanyFILO (French Innovative Leukemia Organisation)
Shares Acute myeloid leukaemia and the tag cooperative-group.
- PersonRichard M. Stone
Shares Acute myeloid leukaemia and the tag cooperative-group.
- TrialCOG AAML0531
Shares ALFA-0701, Acute myeloid leukaemia.
- TargetCD33
Shares ALFA-0701, Acute myeloid leukaemia.
- TreatmentGemtuzumab ozogamicin
Shares ALFA-0701, Acute myeloid leukaemia.
- TreatmentCytarabine + anthracycline ('7+3')
Shares ALFA-0701, Acute myeloid leukaemia.